Seeking Alpha

The Supreme Court says the FTC can take action against deals struck between brand-name drug...

The Supreme Court says the FTC can take action against deals struck between brand-name drug makers and manufacturers seeking to market generics. The case stems from FTC v. Actavis and revolves around so-called "reverse-payment agreements," so named because the holder of a patent makes a payment to the generic challenger as opposed to the other way around. Some say the agreements amount to the splitting of monopoly profits at the expense of the public. Shares of Actavis (ACT -1.7%) fall on the news and Abbvie (ABBV +0.1%) trades largely flat after slipping initially.
Comments (1)
  • hwyram
    , contributor
    Comments (4) | Send Message
     
    It seems these generic companies are ONLY there to make money at the expense of the consumer and their health. Isn't this like Legal Stealing. More control and close watch needs to be kept on these so called "Legit" transactions. Actavis nee Watson is a major player in this conspiracy.
    12 Jul 2013, 09:28 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|